Luxendo closes €6m series-A
EMBL Ventures and Life Sciences Partners (LSP) have backed the €6m series-A for Luxendo, a developer of single-plane illumination microscopes.
With the fresh capital, the company plans to further develop its product, which is scheduled to go on sale in 2016.
EMBL's Stefan Herr and LSP's Joachim Rothe will join Luxendo's board.
EMBL invests throughout Europe in life-science companies. The VC manages €68m on behalf of major European institutional and private investors and typically invests €3-5m as a lead or co-lead investor.
LSP offers seed, early-stage and late-stage financing to private and public life-science companies. It prefers to invest in small and mid-cap companies operating in healthcare and biotechnology sectors across Europe and the US.
Company
Founded in 2015 and based in Heidelberg, Luxendo is a spinout from the European Molecular Biology Laboratory (EMBL). Single-plane illumination microscopes combine optical sectioning with multiple-view imaging to observe tissues and living organisms in high resolution.
People
Stefan Herr is a partner at EMBL. Joachim Rothe is a partner at LSP. Lars Hufnagel led the team that developed the microscope.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









